Last reviewed · How we verify
placebo + CBT
Placebo combined with cognitive behavioral therapy (CBT) leverages psychological intervention and expectancy effects to modify maladaptive thought patterns and behaviors associated with substance use disorders.
Placebo combined with cognitive behavioral therapy (CBT) leverages psychological intervention and expectancy effects to modify maladaptive thought patterns and behaviors associated with substance use disorders. Used for Substance use disorders (cocaine, opioid, cannabis, and other drug dependencies), Co-occurring psychiatric conditions in the context of addiction treatment.
At a glance
| Generic name | placebo + CBT |
|---|---|
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Substance Use Disorder |
| Phase | FDA-approved |
Mechanism of action
CBT is a structured psychotherapeutic approach that helps patients identify and challenge distorted thinking patterns, develop coping strategies, and modify behaviors that reinforce drug use. When combined with placebo, the expectancy and therapeutic alliance may enhance treatment engagement and outcomes. This combination addresses both the psychological and behavioral components of addiction without pharmacological intervention.
Approved indications
- Substance use disorders (cocaine, opioid, cannabis, and other drug dependencies)
- Co-occurring psychiatric conditions in the context of addiction treatment
Common side effects
- Therapeutic non-response or relapse
- Psychological distress during treatment
- Dropout from treatment
Key clinical trials
- N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use (PHASE4)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (PHASE4)
- Mindfulness And Placebo for Pain (MAPP) Study (NA)
- Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth (PHASE3)
- Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder (PHASE3)
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (PHASE3)
- Poor Sleep During Pregnancy as Risk Factor for Post-partum Stress and Mental Health (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |